Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

BACKGROUND: A relevant percentage of patients with metastatic renal cell carcinoma develop intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr-TKIs) and require careful selection of subsequent treatment. This retrospective analysis evaluated the safety and ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Bracarda, S, Hutson, T E, Porta, C, Figlin, R A, Calvo, E, Grünwald, V, Ravaud, A, Motzer, R, Kim, D, Anak, O, Panneerselvam, A, Escudier, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341863/
https://www.ncbi.nlm.nih.gov/pubmed/22441644
http://dx.doi.org/10.1038/bjc.2012.89

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341863/
https://www.ncbi.nlm.nih.gov/pubmed/22441644
http://dx.doi.org/10.1038/bjc.2012.89

Ejemplares similares